These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 16733698)

  • 1. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.
    Amer DA; Irvine GB; El-Agnaf OM
    Exp Brain Res; 2006 Aug; 173(2):223-33. PubMed ID: 16733698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of α-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches.
    Al-Mansoori KM; Hasan MY; Al-Hayani A; El-Agnaf OM
    Curr Alzheimer Res; 2013 Jul; 10(6):559-68. PubMed ID: 23899170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
    Benskey MJ; Perez RG; Manfredsson FP
    J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.
    Paleologou KE; Irvine GB; El-Agnaf OM
    Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders.
    Ono K; Hirohata M; Yamada M
    Curr Pharm Des; 2008; 14(30):3247-66. PubMed ID: 19075704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
    Kalsoom I; Wang Y; Li B; Wen H
    Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropathology of synuclein aggregates.
    Duda JE; Lee VM; Trojanowski JQ
    J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
    Luk KC; Hyde EG; Trojanowski JQ; Lee VM
    Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease and other alpha-synucleinopathies.
    Goedert M
    Clin Chem Lab Med; 2001 Apr; 39(4):308-12. PubMed ID: 11388653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Could α-synuclein amyloid-like aggregates trigger a prionic neuronal invasion?
    Busquets MA; Espargaró A; Estelrich J; Sabate R
    Biomed Res Int; 2015; 2015():172018. PubMed ID: 25866763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hexapeptide PGVTAV suppresses neurotoxicity of human α-synuclein aggregates.
    Choi MY; Kim YS; Lim D; Kang SJ; Kim YH; Lee K; Im H
    Biochem Biophys Res Commun; 2011 May; 408(2):334-8. PubMed ID: 21510923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.
    Peelaerts W; Bousset L; Van der Perren A; Moskalyuk A; Pulizzi R; Giugliano M; Van den Haute C; Melki R; Baekelandt V
    Nature; 2015 Jun; 522(7556):340-4. PubMed ID: 26061766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models.
    Su LJ; Auluck PK; Outeiro TF; Yeger-Lotem E; Kritzer JA; Tardiff DF; Strathearn KE; Liu F; Cao S; Hamamichi S; Hill KJ; Caldwell KA; Bell GW; Fraenkel E; Cooper AA; Caldwell GA; McCaffery JM; Rochet JC; Lindquist S
    Dis Model Mech; 2010; 3(3-4):194-208. PubMed ID: 20038714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment.
    Duran R; Barrero FJ; Morales B; Luna JD; Ramirez M; Vives F
    Mov Disord; 2010 Mar; 25(4):489-93. PubMed ID: 20063406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease.
    Rott R; Szargel R; Shani V; Bisharat S; Engelender S
    CNS Neurol Disord Drug Targets; 2014; 13(4):630-7. PubMed ID: 24168368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of alpha-synuclein in Parkinson's disease].
    Miklya I; Pencz N; Hafenscher F; Göltl P
    Neuropsychopharmacol Hung; 2014 Jun; 16(2):77-84. PubMed ID: 24978050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.